ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.330
+0.090 (4.02%)
At close: Jan 9, 2026, 4:00 PM EST
2.360
+0.030 (1.29%)
After-hours: Jan 9, 2026, 7:59 PM EST
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $2.29 billion as of January 9, 2026. Its market cap has increased by 17.72% in one year.
Market Cap
2.29B
Enterprise Value
2.90B
1-Year Change
17.72%
Ranking
Category
Stock Price
$2.33
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $2.29B, a decrease of -84.52%. That is a compound annual growth rate of -31.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 2.29B | 17.68% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | 14.82B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 952.29B |
| Johnson & Johnson | 492.44B |
| AbbVie | 388.97B |
| UnitedHealth Group | 311.59B |
| AstraZeneca | 295.57B |
| Merck & Co. | 274.34B |
| Novartis AG | 272.98B |
| Novo Nordisk | 263.81B |